nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cytarabine—Gemcitabine—breast cancer	0.324	0.513	CrCrCtD
Regadenoson—Azacitidine—Gemcitabine—breast cancer	0.308	0.487	CrCrCtD
Regadenoson—Azacitidine—DNMT3A—breast cancer	0.00153	0.133	CrCbGaD
Regadenoson—Adenosine triphosphate—ARAF—breast cancer	0.0014	0.122	CrCbGaD
Regadenoson—Azacitidine—CDA—breast cancer	0.00137	0.119	CrCbGaD
Regadenoson—Adenosine monophosphate—PIM1—breast cancer	0.000929	0.0807	CrCbGaD
Regadenoson—Azacitidine—DNMT1—breast cancer	0.000828	0.0719	CrCbGaD
Regadenoson—Adenosine triphosphate—HSPA1B—breast cancer	0.000805	0.07	CrCbGaD
Regadenoson—Adenosine monophosphate—APRT—breast cancer	0.00079	0.0686	CrCbGaD
Regadenoson—Cytarabine—CDA—breast cancer	0.00078	0.0678	CrCbGaD
Regadenoson—Adenosine triphosphate—ACVR1—breast cancer	0.000685	0.0595	CrCbGaD
Regadenoson—Adenosine triphosphate—ALK—breast cancer	0.00037	0.0321	CrCbGaD
Regadenoson—S-Adenosylmethionine—COMT—breast cancer	0.000334	0.0291	CrCbGaD
Regadenoson—Adenosine monophosphate—PDE4D—breast cancer	0.000325	0.0283	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—breast cancer	0.000289	0.0251	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—breast cancer	0.000284	0.0247	CrCbGaD
Regadenoson—Adenosine triphosphate—ABL1—breast cancer	0.000273	0.0237	CrCbGaD
Regadenoson—Clofarabine—ABCG2—breast cancer	0.000248	0.0215	CrCbGaD
Regadenoson—Cladribine—ABCG2—breast cancer	0.000142	0.0124	CrCbGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR1—breast cancer	0.000119	0.00225	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—breast cancer	0.000118	0.00223	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGTR1—breast cancer	0.000117	0.00222	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RGS2—breast cancer	0.000114	0.00215	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCL20—breast cancer	0.000112	0.00213	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCDC88C—breast cancer	0.00011	0.00209	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LGR6—breast cancer	0.00011	0.00209	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—LPAR1—breast cancer	0.000109	0.00206	CbGpPWpGaD
Regadenoson—Arthralgia—Capecitabine—breast cancer	0.000107	0.000352	CcSEcCtD
Regadenoson—Pain—Paclitaxel—breast cancer	0.000107	0.000352	CcSEcCtD
Regadenoson—Anxiety—Capecitabine—breast cancer	0.000107	0.000351	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—NFKBIA—breast cancer	0.000106	0.00201	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000106	0.00035	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—breast cancer	0.000106	0.000349	CcSEcCtD
Regadenoson—Discomfort—Capecitabine—breast cancer	0.000106	0.000348	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—breast cancer	0.000105	0.002	CbGpPWpGaD
Regadenoson—Nausea—Thiotepa—breast cancer	0.000105	0.000347	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—breast cancer	0.000105	0.00199	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SFRP1—breast cancer	0.000105	0.00199	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GPER1—breast cancer	0.000105	0.00199	CbGpPWpGaD
Regadenoson—Diarrhoea—Irinotecan—breast cancer	0.000105	0.000345	CcSEcCtD
Regadenoson—Diarrhoea—Mitoxantrone—breast cancer	0.000105	0.000345	CcSEcCtD
Regadenoson—Shock—Docetaxel—breast cancer	0.000104	0.000343	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—breast cancer	0.000104	0.00197	CbGpPWpGaD
Regadenoson—Nervous system disorder—Docetaxel—breast cancer	0.000104	0.000342	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—breast cancer	0.000103	0.00034	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—RGS2—breast cancer	0.000103	0.00196	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KIT—breast cancer	0.000103	0.00195	CbGpPWpGaD
Regadenoson—Feeling abnormal—Paclitaxel—breast cancer	0.000103	0.000339	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—breast cancer	0.000103	0.000339	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PDE4D—breast cancer	0.000103	0.00195	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—breast cancer	0.000103	0.00194	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—breast cancer	0.000103	0.00194	CbGpPWpGaD
Regadenoson—Bradycardia—Epirubicin—breast cancer	0.000102	0.000337	CcSEcCtD
Regadenoson—Gastrointestinal pain—Paclitaxel—breast cancer	0.000102	0.000336	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CCL20—breast cancer	0.000102	0.00193	CbGpPWpGaD
Regadenoson—Diarrhoea—Gemcitabine—breast cancer	0.000102	0.000336	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—breast cancer	0.000102	0.000335	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—EGF—breast cancer	0.000102	0.00193	CbGpPWpGaD
Regadenoson—Dizziness—Irinotecan—breast cancer	0.000101	0.000333	CcSEcCtD
Regadenoson—Shock—Capecitabine—breast cancer	0.000101	0.000332	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—NMBR—breast cancer	0.000101	0.00191	CbGpPWpGaD
Regadenoson—Nervous system disorder—Capecitabine—breast cancer	0.000101	0.000331	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—breast cancer	0.0001	0.00033	CcSEcCtD
Regadenoson—Diarrhoea—Fluorouracil—breast cancer	0.0001	0.00033	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR2—breast cancer	0.0001	0.0019	CbGpPWpGaD
Regadenoson—Tinnitus—Methotrexate—breast cancer	0.0001	0.00033	CcSEcCtD
Regadenoson—Tachycardia—Capecitabine—breast cancer	0.0001	0.000329	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—breast cancer	0.0001	0.000329	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—breast cancer	9.97e-05	0.000328	CcSEcCtD
Regadenoson—Skin disorder—Capecitabine—breast cancer	9.96e-05	0.000328	CcSEcCtD
Regadenoson—Urticaria—Paclitaxel—breast cancer	9.93e-05	0.000327	CcSEcCtD
Regadenoson—Hyperhidrosis—Capecitabine—breast cancer	9.91e-05	0.000326	CcSEcCtD
Regadenoson—Hypotension—Docetaxel—breast cancer	9.9e-05	0.000326	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—LPAR1—breast cancer	9.89e-05	0.00187	CbGpPWpGaD
Regadenoson—Connective tissue disorder—Epirubicin—breast cancer	9.88e-05	0.000325	CcSEcCtD
Regadenoson—Abdominal pain—Paclitaxel—breast cancer	9.88e-05	0.000325	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—breast cancer	9.75e-05	0.000321	CcSEcCtD
Regadenoson—Vomiting—Mitoxantrone—breast cancer	9.74e-05	0.000321	CcSEcCtD
Regadenoson—Vomiting—Irinotecan—breast cancer	9.74e-05	0.000321	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—breast cancer	9.71e-05	0.000319	CcSEcCtD
Regadenoson—Dizziness—Fluorouracil—breast cancer	9.7e-05	0.000319	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—breast cancer	9.68e-05	0.000319	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—BRAF—breast cancer	9.68e-05	0.00183	CbGpPWpGaD
Regadenoson—Rash—Mitoxantrone—breast cancer	9.66e-05	0.000318	CcSEcCtD
Regadenoson—Rash—Irinotecan—breast cancer	9.66e-05	0.000318	CcSEcCtD
Regadenoson—Dermatitis—Mitoxantrone—breast cancer	9.65e-05	0.000318	CcSEcCtD
Regadenoson—Dermatitis—Irinotecan—breast cancer	9.65e-05	0.000318	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Docetaxel—breast cancer	9.65e-05	0.000318	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—breast cancer	9.63e-05	0.00182	CbGpPWpGaD
Regadenoson—Headache—Irinotecan—breast cancer	9.6e-05	0.000316	CcSEcCtD
Regadenoson—Headache—Mitoxantrone—breast cancer	9.6e-05	0.000316	CcSEcCtD
Regadenoson—Hypotension—Capecitabine—breast cancer	9.58e-05	0.000315	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—breast cancer	9.58e-05	0.000315	CcSEcCtD
Regadenoson—Paraesthesia—Docetaxel—breast cancer	9.51e-05	0.000313	CcSEcCtD
Regadenoson—Vomiting—Gemcitabine—breast cancer	9.49e-05	0.000312	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—breast cancer	9.47e-05	0.000312	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—breast cancer	9.44e-05	0.000311	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—AKT2—breast cancer	9.43e-05	0.00179	CbGpPWpGaD
Regadenoson—Somnolence—Docetaxel—breast cancer	9.42e-05	0.00031	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—breast cancer	9.41e-05	0.00031	CcSEcCtD
Regadenoson—Rash—Gemcitabine—breast cancer	9.41e-05	0.00031	CcSEcCtD
Regadenoson—Dermatitis—Gemcitabine—breast cancer	9.4e-05	0.000309	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—breast cancer	9.4e-05	0.000309	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—breast cancer	9.38e-05	0.000309	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—HEYL—breast cancer	9.36e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CUL5—breast cancer	9.36e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTGER1—breast cancer	9.36e-05	0.00177	CbGpPWpGaD
Regadenoson—Erythema—Methotrexate—breast cancer	9.35e-05	0.000308	CcSEcCtD
Regadenoson—Headache—Gemcitabine—breast cancer	9.35e-05	0.000308	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—JUN—breast cancer	9.35e-05	0.00177	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Capecitabine—breast cancer	9.34e-05	0.000307	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PDE4D—breast cancer	9.34e-05	0.00177	CbGpPWpGaD
Regadenoson—Flushing—Epirubicin—breast cancer	9.33e-05	0.000307	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—breast cancer	9.33e-05	0.000307	CcSEcCtD
Regadenoson—Vomiting—Fluorouracil—breast cancer	9.33e-05	0.000307	CcSEcCtD
Regadenoson—Insomnia—Capecitabine—breast cancer	9.28e-05	0.000305	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—breast cancer	9.26e-05	0.000305	CcSEcCtD
Regadenoson—Rash—Fluorouracil—breast cancer	9.25e-05	0.000304	CcSEcCtD
Regadenoson—Dermatitis—Fluorouracil—breast cancer	9.24e-05	0.000304	CcSEcCtD
Regadenoson—Paraesthesia—Capecitabine—breast cancer	9.21e-05	0.000303	CcSEcCtD
Regadenoson—Hypersensitivity—Paclitaxel—breast cancer	9.21e-05	0.000303	CcSEcCtD
Regadenoson—Headache—Fluorouracil—breast cancer	9.19e-05	0.000303	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—breast cancer	9.16e-05	0.000301	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Docetaxel—breast cancer	9.14e-05	0.000301	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—breast cancer	9.14e-05	0.000301	CcSEcCtD
Regadenoson—Dyspnoea—Capecitabine—breast cancer	9.14e-05	0.000301	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—breast cancer	9.12e-05	0.0003	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CNR2—breast cancer	9.1e-05	0.00172	CbGpPWpGaD
Regadenoson—Nausea—Irinotecan—breast cancer	9.1e-05	0.000299	CcSEcCtD
Regadenoson—Nausea—Mitoxantrone—breast cancer	9.1e-05	0.000299	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—breast cancer	9.08e-05	0.000299	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—breast cancer	9.06e-05	0.000298	CcSEcCtD
Regadenoson—Pain—Docetaxel—breast cancer	9.06e-05	0.000298	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—breast cancer	9.06e-05	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—breast cancer	9.04e-05	0.00171	CbGpPWpGaD
Regadenoson—Asthenia—Paclitaxel—breast cancer	8.97e-05	0.000295	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—breast cancer	8.89e-05	0.00168	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—breast cancer	8.87e-05	0.00168	CbGpPWpGaD
Regadenoson—Nausea—Gemcitabine—breast cancer	8.87e-05	0.000292	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Capecitabine—breast cancer	8.85e-05	0.000291	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—MAPK8—breast cancer	8.85e-05	0.00168	CbGpPWpGaD
Regadenoson—Vision blurred—Methotrexate—breast cancer	8.82e-05	0.00029	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—breast cancer	8.81e-05	0.00029	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—RSPO3—breast cancer	8.8e-05	0.00167	CbGpPWpGaD
Regadenoson—Pain—Capecitabine—breast cancer	8.77e-05	0.000289	CcSEcCtD
Regadenoson—Erythema—Epirubicin—breast cancer	8.75e-05	0.000288	CcSEcCtD
Regadenoson—Feeling abnormal—Docetaxel—breast cancer	8.73e-05	0.000287	CcSEcCtD
Regadenoson—Nausea—Fluorouracil—breast cancer	8.72e-05	0.000287	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—breast cancer	8.7e-05	0.000286	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—breast cancer	8.68e-05	0.000286	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—breast cancer	8.68e-05	0.000285	CcSEcCtD
Regadenoson—Gastrointestinal pain—Docetaxel—breast cancer	8.66e-05	0.000285	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—breast cancer	8.64e-05	0.000284	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—breast cancer	8.64e-05	0.000284	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—AGTR2—breast cancer	8.62e-05	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL2—breast cancer	8.62e-05	0.00163	CbGpPWpGaD
Regadenoson—Dysgeusia—Epirubicin—breast cancer	8.57e-05	0.000282	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—WNT10B—breast cancer	8.56e-05	0.00162	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WWOX—breast cancer	8.56e-05	0.00162	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—WNT1—breast cancer	8.56e-05	0.00162	CbGpPWpGaD
Regadenoson—Diarrhoea—Paclitaxel—breast cancer	8.55e-05	0.000281	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PTHLH—breast cancer	8.52e-05	0.00161	CbGpPWpGaD
Regadenoson—Feeling abnormal—Capecitabine—breast cancer	8.45e-05	0.000278	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—breast cancer	8.44e-05	0.000278	CcSEcCtD
Regadenoson—Malaise—Methotrexate—breast cancer	8.44e-05	0.000278	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—breast cancer	8.4e-05	0.000277	CcSEcCtD
Regadenoson—Gastrointestinal pain—Capecitabine—breast cancer	8.39e-05	0.000276	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—breast cancer	8.39e-05	0.000276	CcSEcCtD
Regadenoson—Abdominal pain—Docetaxel—breast cancer	8.37e-05	0.000276	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CXCL3—breast cancer	8.34e-05	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDE2A—breast cancer	8.34e-05	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INHBB—breast cancer	8.34e-05	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL27—breast cancer	8.34e-05	0.00158	CbGpPWpGaD
Regadenoson—Dizziness—Paclitaxel—breast cancer	8.26e-05	0.000272	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—EDNRB—breast cancer	8.25e-05	0.00156	CbGpPWpGaD
Regadenoson—Vision blurred—Epirubicin—breast cancer	8.25e-05	0.000271	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—breast cancer	8.22e-05	0.00156	CbGpPWpGaD
Regadenoson—Cough—Methotrexate—breast cancer	8.16e-05	0.000269	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—breast cancer	8.15e-05	0.000268	CcSEcCtD
Regadenoson—Urticaria—Capecitabine—breast cancer	8.15e-05	0.000268	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—breast cancer	8.12e-05	0.000267	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MDM2—breast cancer	8.11e-05	0.00154	CbGpPWpGaD
Regadenoson—Abdominal pain—Capecitabine—breast cancer	8.11e-05	0.000267	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—breast cancer	8.1e-05	0.000267	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—breast cancer	8.1e-05	0.000267	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—RAF1—breast cancer	8.08e-05	0.00153	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RELA—breast cancer	8.05e-05	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—breast cancer	8e-05	0.00152	CbGpPWpGaD
Regadenoson—Chest pain—Methotrexate—breast cancer	7.96e-05	0.000262	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—breast cancer	7.96e-05	0.000262	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—breast cancer	7.96e-05	0.000262	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—BMPR2—breast cancer	7.96e-05	0.00151	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DLL4—breast cancer	7.96e-05	0.00151	CbGpPWpGaD
Regadenoson—Vomiting—Paclitaxel—breast cancer	7.95e-05	0.000261	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—breast cancer	7.93e-05	0.000261	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—breast cancer	7.93e-05	0.0015	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	7.91e-05	0.00026	CcSEcCtD
Regadenoson—Malaise—Epirubicin—breast cancer	7.89e-05	0.00026	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MTOR—breast cancer	7.89e-05	0.0015	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—breast cancer	7.89e-05	0.0015	CbGpPWpGaD
Regadenoson—Rash—Paclitaxel—breast cancer	7.88e-05	0.000259	CcSEcCtD
Regadenoson—Dermatitis—Paclitaxel—breast cancer	7.87e-05	0.000259	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—breast cancer	7.87e-05	0.000259	CcSEcCtD
Regadenoson—Syncope—Epirubicin—breast cancer	7.85e-05	0.000258	CcSEcCtD
Regadenoson—Headache—Paclitaxel—breast cancer	7.83e-05	0.000258	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL2—breast cancer	7.83e-05	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGTR2—breast cancer	7.83e-05	0.00148	CbGpPWpGaD
Regadenoson—Hypersensitivity—Docetaxel—breast cancer	7.8e-05	0.000257	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PTHLH—breast cancer	7.74e-05	0.00147	CbGpPWpGaD
Regadenoson—Palpitations—Epirubicin—breast cancer	7.74e-05	0.000255	CcSEcCtD
Regadenoson—Cytarabine—CYP3A4—breast cancer	7.74e-05	0.00672	CrCbGaD
Regadenoson—Loss of consciousness—Epirubicin—breast cancer	7.69e-05	0.000253	CcSEcCtD
Regadenoson—Cough—Epirubicin—breast cancer	7.64e-05	0.000251	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—breast cancer	7.63e-05	0.000251	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—breast cancer	7.63e-05	0.000251	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CDH5—breast cancer	7.63e-05	0.00145	CbGpPWpGaD
Regadenoson—Asthenia—Docetaxel—breast cancer	7.6e-05	0.00025	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—breast cancer	7.58e-05	0.00025	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—breast cancer	7.58e-05	0.00144	CbGpPWpGaD
Regadenoson—Hypertension—Epirubicin—breast cancer	7.56e-05	0.000249	CcSEcCtD
Regadenoson—Hypersensitivity—Capecitabine—breast cancer	7.56e-05	0.000249	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—breast cancer	7.52e-05	0.000247	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CALCA—breast cancer	7.5e-05	0.00142	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDNRB—breast cancer	7.5e-05	0.00142	CbGpPWpGaD
Regadenoson—Nervous system disorder—Methotrexate—breast cancer	7.49e-05	0.000246	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—SFRP2—breast cancer	7.48e-05	0.00142	CbGpPWpGaD
Regadenoson—Myalgia—Epirubicin—breast cancer	7.45e-05	0.000245	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—breast cancer	7.45e-05	0.000245	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—breast cancer	7.45e-05	0.000245	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—breast cancer	7.43e-05	0.000244	CcSEcCtD
Regadenoson—Nausea—Paclitaxel—breast cancer	7.42e-05	0.000244	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—breast cancer	7.42e-05	0.000244	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1B—breast cancer	7.41e-05	0.0014	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	7.4e-05	0.000244	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—breast cancer	7.38e-05	0.000243	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—breast cancer	7.36e-05	0.000242	CcSEcCtD
Regadenoson—Asthenia—Capecitabine—breast cancer	7.36e-05	0.000242	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PRLR—breast cancer	7.35e-05	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCR4—breast cancer	7.33e-05	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL12—breast cancer	7.33e-05	0.00139	CbGpPWpGaD
Regadenoson—Malaise—Doxorubicin—breast cancer	7.3e-05	0.00024	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—breast cancer	7.26e-05	0.000239	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—breast cancer	7.26e-05	0.00138	CbGpPWpGaD
Regadenoson—Diarrhoea—Docetaxel—breast cancer	7.25e-05	0.000238	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—breast cancer	7.21e-05	0.00137	CbGpPWpGaD
Regadenoson—Palpitations—Doxorubicin—breast cancer	7.16e-05	0.000236	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—breast cancer	7.14e-05	0.000235	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—breast cancer	7.13e-05	0.000235	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—breast cancer	7.12e-05	0.000234	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GLI2—breast cancer	7.1e-05	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VCP—breast cancer	7.1e-05	0.00134	CbGpPWpGaD
Regadenoson—Cough—Doxorubicin—breast cancer	7.07e-05	0.000233	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	7.06e-05	0.00134	CbGpPWpGaD
Regadenoson—Shock—Epirubicin—breast cancer	7.03e-05	0.000231	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—breast cancer	7.02e-05	0.000231	CcSEcCtD
Regadenoson—Diarrhoea—Capecitabine—breast cancer	7.02e-05	0.000231	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—breast cancer	7.01e-05	0.000231	CcSEcCtD
Regadenoson—Dizziness—Docetaxel—breast cancer	7e-05	0.00023	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—breast cancer	6.99e-05	0.00023	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—LEPR—breast cancer	6.98e-05	0.00132	CbGpPWpGaD
Regadenoson—Tachycardia—Epirubicin—breast cancer	6.97e-05	0.000229	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—breast cancer	6.96e-05	0.000229	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—breast cancer	6.94e-05	0.000228	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—breast cancer	6.91e-05	0.000227	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—breast cancer	6.9e-05	0.000227	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—breast cancer	6.9e-05	0.000227	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—breast cancer	6.9e-05	0.000227	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—breast cancer	6.9e-05	0.000227	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—breast cancer	6.87e-05	0.000226	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—breast cancer	6.86e-05	0.000226	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	6.85e-05	0.000225	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—breast cancer	6.84e-05	0.0013	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—breast cancer	6.82e-05	0.00129	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CALCA—breast cancer	6.81e-05	0.00129	CbGpPWpGaD
Regadenoson—Discomfort—Doxorubicin—breast cancer	6.81e-05	0.000224	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—breast cancer	6.81e-05	0.00129	CbGpPWpGaD
Regadenoson—Dyspnoea—Methotrexate—breast cancer	6.81e-05	0.000224	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—breast cancer	6.79e-05	0.000223	CcSEcCtD
Regadenoson—Dizziness—Capecitabine—breast cancer	6.78e-05	0.000223	CcSEcCtD
Regadenoson—Vomiting—Docetaxel—breast cancer	6.73e-05	0.000222	CcSEcCtD
Regadenoson—Rash—Docetaxel—breast cancer	6.68e-05	0.00022	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—breast cancer	6.68e-05	0.00022	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—breast cancer	6.67e-05	0.00022	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MAPK8—breast cancer	6.67e-05	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL12—breast cancer	6.66e-05	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCR4—breast cancer	6.66e-05	0.00126	CbGpPWpGaD
Regadenoson—Headache—Docetaxel—breast cancer	6.64e-05	0.000218	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—AGTR1—breast cancer	6.63e-05	0.00126	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Doxorubicin—breast cancer	6.61e-05	0.000218	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—breast cancer	6.59e-05	0.000217	CcSEcCtD
Regadenoson—Pain—Methotrexate—breast cancer	6.53e-05	0.000215	CcSEcCtD
Regadenoson—Vomiting—Capecitabine—breast cancer	6.52e-05	0.000215	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—breast cancer	6.51e-05	0.000214	CcSEcCtD
Regadenoson—Shock—Doxorubicin—breast cancer	6.5e-05	0.000214	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—ARHGDIA—breast cancer	6.49e-05	0.00123	CbGpPWpGaD
Regadenoson—Nervous system disorder—Doxorubicin—breast cancer	6.48e-05	0.000213	CcSEcCtD
Regadenoson—Rash—Capecitabine—breast cancer	6.47e-05	0.000213	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—breast cancer	6.46e-05	0.000213	CcSEcCtD
Regadenoson—Dermatitis—Capecitabine—breast cancer	6.46e-05	0.000213	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—breast cancer	6.45e-05	0.000212	CcSEcCtD
Regadenoson—Headache—Capecitabine—breast cancer	6.42e-05	0.000211	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—breast cancer	6.42e-05	0.000211	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—breast cancer	6.42e-05	0.000211	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—breast cancer	6.39e-05	0.00021	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—breast cancer	6.37e-05	0.00021	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—breast cancer	6.35e-05	0.000209	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—SRC—breast cancer	6.33e-05	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FST—breast cancer	6.32e-05	0.0012	CbGpPWpGaD
Regadenoson—Nausea—Docetaxel—breast cancer	6.29e-05	0.000207	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—breast cancer	6.29e-05	0.000207	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—breast cancer	6.26e-05	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HEY2—breast cancer	6.25e-05	0.00118	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Methotrexate—breast cancer	6.24e-05	0.000205	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—breast cancer	6.18e-05	0.000203	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—RPS6KB2—breast cancer	6.17e-05	0.00117	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—breast cancer	6.17e-05	0.00117	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Epirubicin—breast cancer	6.17e-05	0.000203	CcSEcCtD
Regadenoson—Pain—Epirubicin—breast cancer	6.11e-05	0.000201	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—RGS2—breast cancer	6.1e-05	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—breast cancer	6.1e-05	0.00116	CbGpPWpGaD
Regadenoson—Nausea—Capecitabine—breast cancer	6.09e-05	0.0002	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—breast cancer	6.06e-05	0.0002	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—breast cancer	6.04e-05	0.000199	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CCL20—breast cancer	6.03e-05	0.00114	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—breast cancer	6.02e-05	0.000198	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—AGTR1—breast cancer	6.02e-05	0.00114	CbGpPWpGaD
Regadenoson—Insomnia—Doxorubicin—breast cancer	5.98e-05	0.000197	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—ITPR1—breast cancer	5.95e-05	0.00113	CbGpPWpGaD
Regadenoson—Paraesthesia—Doxorubicin—breast cancer	5.94e-05	0.000195	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—breast cancer	5.89e-05	0.000194	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—breast cancer	5.89e-05	0.000194	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—breast cancer	5.88e-05	0.000193	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—TLE3—breast cancer	5.84e-05	0.00111	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LPAR1—breast cancer	5.84e-05	0.00111	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Epirubicin—breast cancer	5.84e-05	0.000192	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—breast cancer	5.83e-05	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—breast cancer	5.79e-05	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HEY1—breast cancer	5.78e-05	0.0011	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Doxorubicin—breast cancer	5.71e-05	0.000188	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—breast cancer	5.68e-05	0.000187	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—DLL1—breast cancer	5.67e-05	0.00107	CbGpPWpGaD
Regadenoson—Pain—Doxorubicin—breast cancer	5.65e-05	0.000186	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—breast cancer	5.65e-05	0.00107	CbGpPWpGaD
Regadenoson—Abdominal pain—Epirubicin—breast cancer	5.65e-05	0.000186	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—breast cancer	5.62e-05	0.000185	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—HIST1H2BK—breast cancer	5.57e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIST1H2BC—breast cancer	5.57e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—breast cancer	5.54e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—breast cancer	5.54e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRB7—breast cancer	5.52e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDE4D—breast cancer	5.52e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CSF2—breast cancer	5.49e-05	0.00104	CbGpPWpGaD
Regadenoson—Asthenia—Methotrexate—breast cancer	5.48e-05	0.00018	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—breast cancer	5.45e-05	0.000179	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—TAB2—breast cancer	5.42e-05	0.00103	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Doxorubicin—breast cancer	5.41e-05	0.000178	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—ITPR1—breast cancer	5.4e-05	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CNR2—breast cancer	5.38e-05	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—breast cancer	5.37e-05	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MMP3—breast cancer	5.36e-05	0.00102	CbGpPWpGaD
Regadenoson—Hypersensitivity—Epirubicin—breast cancer	5.26e-05	0.000173	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—breast cancer	5.25e-05	0.000173	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—DKK1—breast cancer	5.25e-05	0.000994	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—breast cancer	5.24e-05	0.000992	CbGpPWpGaD
Regadenoson—Abdominal pain—Doxorubicin—breast cancer	5.23e-05	0.000172	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—breast cancer	5.22e-05	0.000172	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—VEGFC—breast cancer	5.21e-05	0.000987	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAG2—breast cancer	5.13e-05	0.000972	CbGpPWpGaD
Regadenoson—Asthenia—Epirubicin—breast cancer	5.13e-05	0.000169	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—breast cancer	5.11e-05	0.000968	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WNT1—breast cancer	5.06e-05	0.000958	CbGpPWpGaD
Regadenoson—Dizziness—Methotrexate—breast cancer	5.05e-05	0.000166	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PLA2G4A—breast cancer	5.04e-05	0.000956	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ABCB1—breast cancer	5.04e-05	0.00438	CrCbGaD
Regadenoson—ADORA2A—Signaling by GPCR—CSF2—breast cancer	4.99e-05	0.000945	CbGpPWpGaD
Regadenoson—Diarrhoea—Epirubicin—breast cancer	4.89e-05	0.000161	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—breast cancer	4.87e-05	0.00016	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—breast cancer	4.85e-05	0.00016	CcSEcCtD
Regadenoson—Rash—Methotrexate—breast cancer	4.81e-05	0.000158	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—breast cancer	4.81e-05	0.000912	CbGpPWpGaD
Regadenoson—Dermatitis—Methotrexate—breast cancer	4.81e-05	0.000158	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH4—breast cancer	4.79e-05	0.000908	CbGpPWpGaD
Regadenoson—Headache—Methotrexate—breast cancer	4.78e-05	0.000157	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GZMB—breast cancer	4.76e-05	0.000902	CbGpPWpGaD
Regadenoson—Asthenia—Doxorubicin—breast cancer	4.74e-05	0.000156	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—breast cancer	4.72e-05	0.000155	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CXCL2—breast cancer	4.62e-05	0.000876	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGTR2—breast cancer	4.62e-05	0.000876	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTHLH—breast cancer	4.57e-05	0.000866	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BMP2—breast cancer	4.57e-05	0.000866	CbGpPWpGaD
Regadenoson—Vomiting—Epirubicin—breast cancer	4.54e-05	0.000149	CcSEcCtD
Regadenoson—Nausea—Methotrexate—breast cancer	4.53e-05	0.000149	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—breast cancer	4.52e-05	0.000149	CcSEcCtD
Regadenoson—Rash—Epirubicin—breast cancer	4.5e-05	0.000148	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—breast cancer	4.5e-05	0.000148	CcSEcCtD
Regadenoson—Headache—Epirubicin—breast cancer	4.48e-05	0.000147	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—HRAS—breast cancer	4.45e-05	0.000843	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDNRB—breast cancer	4.43e-05	0.000839	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PGR—breast cancer	4.38e-05	0.00083	CbGpPWpGaD
Regadenoson—Dizziness—Doxorubicin—breast cancer	4.37e-05	0.000144	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—THBS1—breast cancer	4.36e-05	0.000826	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—breast cancer	4.26e-05	0.000807	CbGpPWpGaD
Regadenoson—Nausea—Epirubicin—breast cancer	4.24e-05	0.00014	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—breast cancer	4.2e-05	0.000138	CcSEcCtD
Regadenoson—Rash—Doxorubicin—breast cancer	4.17e-05	0.000137	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—breast cancer	4.16e-05	0.000137	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—FLT1—breast cancer	4.16e-05	0.000789	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF3—breast cancer	4.15e-05	0.000785	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SQSTM1—breast cancer	4.15e-05	0.000785	CbGpPWpGaD
Regadenoson—Headache—Doxorubicin—breast cancer	4.14e-05	0.000136	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—breast cancer	4.12e-05	0.000781	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAG1—breast cancer	4.09e-05	0.000775	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH3—breast cancer	4.08e-05	0.000772	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PARP1—breast cancer	4.08e-05	0.000772	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CALCA—breast cancer	4.03e-05	0.000763	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RPS6—breast cancer	3.98e-05	0.000754	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF4—breast cancer	3.95e-05	0.000748	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL12—breast cancer	3.93e-05	0.000745	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCR4—breast cancer	3.93e-05	0.000745	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—breast cancer	3.93e-05	0.000745	CbGpPWpGaD
Regadenoson—Nausea—Doxorubicin—breast cancer	3.93e-05	0.000129	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PAK1—breast cancer	3.86e-05	0.000731	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TCF7L2—breast cancer	3.79e-05	0.000718	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT2—breast cancer	3.77e-05	0.000715	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—breast cancer	3.75e-05	0.00071	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH2—breast cancer	3.66e-05	0.000692	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HSP90AA1—breast cancer	3.66e-05	0.000692	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—breast cancer	3.63e-05	0.000687	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGTR1—breast cancer	3.56e-05	0.000674	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRL—breast cancer	3.56e-05	0.000674	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STK11—breast cancer	3.5e-05	0.000664	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADAM10—breast cancer	3.5e-05	0.000664	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLG—breast cancer	3.47e-05	0.000656	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT2—breast cancer	3.43e-05	0.000649	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF10—breast cancer	3.41e-05	0.000646	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—breast cancer	3.29e-05	0.000624	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFA—breast cancer	3.29e-05	0.000623	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFBR2—breast cancer	3.24e-05	0.000614	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ITPR1—breast cancer	3.19e-05	0.000604	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB4—breast cancer	3.17e-05	0.0006	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP3—breast cancer	3.17e-05	0.0006	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT5A—breast cancer	3.17e-05	0.0006	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—breast cancer	3.16e-05	0.000599	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SMAD4—breast cancer	3.07e-05	0.000581	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1R—breast cancer	3.05e-05	0.000578	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—breast cancer	3.04e-05	0.000575	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HES1—breast cancer	3e-05	0.000568	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCOR1—breast cancer	2.98e-05	0.000564	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLA2G4A—breast cancer	2.98e-05	0.000564	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF1—breast cancer	2.95e-05	0.000558	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CSF2—breast cancer	2.95e-05	0.000558	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAF1—breast cancer	2.94e-05	0.000557	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NRG1—breast cancer	2.92e-05	0.000554	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—H2AFX—breast cancer	2.9e-05	0.00055	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—breast cancer	2.9e-05	0.00055	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—E2F1—breast cancer	2.88e-05	0.000546	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—breast cancer	2.87e-05	0.000544	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPP1—breast cancer	2.77e-05	0.000525	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—breast cancer	2.76e-05	0.000522	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB3—breast cancer	2.74e-05	0.000519	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR2—breast cancer	2.74e-05	0.000518	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—breast cancer	2.64e-05	0.000499	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TERT—breast cancer	2.63e-05	0.000497	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR1—breast cancer	2.55e-05	0.000483	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—breast cancer	2.51e-05	0.000476	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—breast cancer	2.45e-05	0.000464	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CAV1—breast cancer	2.43e-05	0.00046	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—breast cancer	2.4e-05	0.000455	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ESR1—breast cancer	2.34e-05	0.000443	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FN1—breast cancer	2.31e-05	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NFKBIA—breast cancer	2.28e-05	0.000433	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH1—breast cancer	2.26e-05	0.000429	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KIT—breast cancer	2.21e-05	0.000419	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—breast cancer	2.21e-05	0.000419	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—breast cancer	2.21e-05	0.000419	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGF—breast cancer	2.19e-05	0.000414	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—breast cancer	2.12e-05	0.000401	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRAF—breast cancer	2.08e-05	0.000394	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—breast cancer	2.03e-05	0.000384	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT2—breast cancer	2.02e-05	0.000383	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—breast cancer	2.02e-05	0.000382	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—breast cancer	1.95e-05	0.000368	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—breast cancer	1.93e-05	0.000365	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—breast cancer	1.92e-05	0.000364	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—breast cancer	1.9e-05	0.000361	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—breast cancer	1.84e-05	0.000348	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—breast cancer	1.75e-05	0.000331	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDM2—breast cancer	1.74e-05	0.00033	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAF1—breast cancer	1.74e-05	0.000329	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RELA—breast cancer	1.73e-05	0.000328	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—breast cancer	1.72e-05	0.000325	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTOR—breast cancer	1.7e-05	0.000321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—breast cancer	1.7e-05	0.000321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—breast cancer	1.63e-05	0.000309	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRAS—breast cancer	1.62e-05	0.000307	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1B—breast cancer	1.59e-05	0.000301	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—breast cancer	1.57e-05	0.000298	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—breast cancer	1.56e-05	0.000295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—breast cancer	1.56e-05	0.000295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—breast cancer	1.55e-05	0.000293	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—breast cancer	1.52e-05	0.000288	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUN—breast cancer	1.51e-05	0.000287	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTNNB1—breast cancer	1.5e-05	0.000285	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—breast cancer	1.47e-05	0.000279	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—breast cancer	1.47e-05	0.000278	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—breast cancer	1.46e-05	0.000278	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK8—breast cancer	1.43e-05	0.000271	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—breast cancer	1.43e-05	0.000271	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SRC—breast cancer	1.36e-05	0.000257	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—breast cancer	1.32e-05	0.000251	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—breast cancer	1.31e-05	0.000248	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—breast cancer	1.25e-05	0.000237	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—breast cancer	1.22e-05	0.000231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—breast cancer	1.21e-05	0.00023	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—breast cancer	1.19e-05	0.000226	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—breast cancer	1.12e-05	0.000213	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—breast cancer	1.03e-05	0.000196	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—breast cancer	1e-05	0.000189	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRAS—breast cancer	9.56e-06	0.000181	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—breast cancer	9.15e-06	0.000173	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—breast cancer	8.44e-06	0.00016	CbGpPWpGaD
